Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Infect ; 32(2): 123-31, 1996 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-8708369

RESUMO

We randomized 220 HIV-1-infected subjects to receive aerosolized pentamidine (300 mg/4 weeks) or orally trimethoprim-sulfamethoxazole (320-1600 mg/day) for primary prophylaxis of Pneumocystis carinii pneumonia (PCP), and evaluated PCP and toxoplasmic encephalitis (TE) occurrence and survival. Patients developing toxicity switched to the other regimen. Analysis was on intention-to-treat. At 1 year of study, we observed in the pentamidine group a non-significant excess of PCP (4 vs. 1) and TE (7 vs. 3), and a significant increased death rate (15 vs. 2). After 2 years, no significant differences were observed: adjusted RR estimates for pentamidine vs. cotrimoxazole were 1.20 (95% CI, 0.33-4.37) for PCP (6 cases vs. 5), 1.23 (95% CI, 0.46-3.29) for TE (10 vs. 8) and 1.52 (95% CI, 0.83-2.79) for death (30 vs. 18). Crossovers were more frequent in the cotrimoxazole group (41 vs. 4, P < 0.001). Aerosolized pentamidine and cotrimoxazole were equally effective in preventing PCP, and no major differences were observed in TE occurrence and survival after 2 years follow-up.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/prevenção & controle , HIV-1 , Pentamidina/uso terapêutico , Pneumonia por Pneumocystis/prevenção & controle , Toxoplasmose Cerebral/prevenção & controle , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Adulto , Aerossóis , Feminino , Humanos , Masculino , Pentamidina/administração & dosagem , Pentamidina/efeitos adversos , Combinação Trimetoprima e Sulfametoxazol/efeitos adversos
2.
J Infect ; 31(2): 99-105, 1995 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-8666860

RESUMO

The aim of this multicentric randomised controlled trial was to evaluate long-term efficacy and safety of once-monthly versus twice-monthly 300 mg aerosolized pentamidine (AP) as secondary prophylaxis of Pneumocystis carinii pneumonia (PCP). We randomised 205 patients with a previous confirmed episode of PCP (107 treated with 300 mg once-monthly AP, and 98 with 300 mg twice monthly AP); the median review period was 232 days. Kaplan-Meier method and Cox's hazard regression model were used for analysis. The main outcome assessments were PCP recurrence, survival and incidence of drug toxicity. The two groups were balanced for prognostic predictors. In the once-monthly AP group, 14 relapses of confirmed PCP were observed, while five occurred in the twice-monthly AP group; the crude relative risk (RR) was 2.69 (95% CI 1.002-7.236, P=0.0496) and the adjusted RR accounting for prognostic predictors was 2.62 (95% CI 0.92-7.5, P=0.071). Death occurred in 36 of 26 patients respectively (adjusted RR 1.32, 95% CI 0.8-2.18, P=0.28). Two patients interrupted the study because of intolerance to AP (one in each group), and severe coughing occurred in two patients (one in each group). At the end of the study, pulmonary function tests were not changed compared with baseline and were the same between the two groups. Our study suggests that 300 mg twice-monthly AP is more effective than 300 mg once-monthly AP as secondary prophylaxis of PCP.


Assuntos
Síndrome da Imunodeficiência Adquirida/complicações , Antifúngicos/administração & dosagem , Pentamidina/administração & dosagem , Pneumonia por Pneumocystis/prevenção & controle , Administração por Inalação , Adulto , Aerossóis , Antifúngicos/uso terapêutico , Esquema de Medicação , Feminino , Humanos , Itália , Masculino , Pentamidina/uso terapêutico , Recidiva , Fatores de Risco
3.
Gen Comp Endocrinol ; 124(2): 246-55, 2001 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-11703089

RESUMO

Steroid hormones play major roles in the organization of the phenotype and in the activation of behavior. From hatching to fledging, they are involved in growth, development, and learning. We investigated the relationship between the ontogenetic patterns of steroid hormones and the sexual and social development of greylag goslings (Anser anser). Two groups of individually marked goslings (n = 10/5) were hand-raised under near-field conditions. 17beta-OH-androgen (AM), estrogen (EM), and corticosterone (BM) immunoreactive metabolites were measured noninvasively by enzyme immunoassay of individual fecal samples. Feces were regularly sampled from hatching to fledging. All excreted steroids were found to peak at hatching and to decrease thereafter. Gonadal steroids fluctuated more than BM, which remained at low levels throughout ontogeny after a slow decrease during the first 20 days. The pattern of BM is discussed in relation to learning processes (i.e., filial imprinting) and social stress. It is suggested that high initial BM may constrain energy allocation to growth. AM increased around the age of 20 days, when the feathers start growing, and later, together with EM, at the age of 40 days. These elevated values of gonadal steroids are discussed in relation to the sensitive phase of sexual imprinting. Females show higher EM levels than males throughout ontogeny. Furthermore, the ratio of excreted estrogen to androgen (EM/AM) of females before fledging correlates with the number of hatched and fledged goslings in their first years of reproduction. In conclusion, our data suggest a role for steroid hormones in the modulation of behavioral and morphological development in the precocial greylag geese, in agreement with the organizational-activational hypothesis.


Assuntos
Androgênios/metabolismo , Corticosterona/metabolismo , Estrogênios/metabolismo , Fezes/química , Gansos/metabolismo , Fatores Etários , Animais , Feminino , Gansos/crescimento & desenvolvimento , Gansos/fisiologia , Masculino , Fatores Sexuais , Comportamento Sexual Animal , Comportamento Social
4.
Ann Vasc Surg ; 12(5): 457-62, 1998 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-9732424

RESUMO

Following the experience of cardiac surgeons with homografts in the treatment of infective aortic valve endocarditis, cardiovascular surgeons have investigated in situ revascularization by means of homografts in the management of vascular prosthetic graft infections. Preliminary results are encouraging, but their late fate in long-term follow-up and the influence of preservation techniques are still under investigation. This article reports the experience of the Italian Collaborative Vascular Homograft Group, with the use of fresh and cryopreserved arterial homografts for the treatment of prosthetic graft infections. Between March 1994 and December 1996, 44 patients with prosthetic graft infection were treated with homografts (13 preserved at 4 degrees C, 31 cryopreserved). The mean age of the patients was 65 years. Emergency surgical procedures were performed in eight patients (18%). Sepsis was diagnosed in 11 patients, aortoenteric fistula in 13, and false aneurysms in 10. Staphylococcus was the main cause of infection. The types of vascular reconstruction with homograft were: 32 aortobifemoral, 3 aortoaortic, 2 iliofemoral, 4 peripheral, and 3 axillobifemoral. Human lymphocyte antigen (HLA) and antibody (ABO) blood group system compatibility between donors and recipients was not respected. The mean duration of follow-up was 15 months (range 1-33). Clinical and duplex scanning evaluations were routinely performed. Computed tomography (CT) or magnetic resonance (MR) scanning or arteriography were performed on the basis of duplex scanning results. There were six deaths during the early postoperative period (30 days) with a mortality rate of 13.6%. During the follow-up there were five late deaths with a mortality rate of 11.4%. Eight patients had graft occlusion. Three cases were successfully treated with thrombectomy. Two cases were successfully treated with femoropopliteal bypass with autologous vein. In three cases leg amputation was necessary. The results of fresh and cryopreserved homograft were compared. No significative differences of early postoperative mortality, late mortality, homograft related mortality, and graft occlusion were observed. We have evaluated the actuarial survival of the patients and the actuarial patency of the homografts on the aortoiliac reconstructions. Twelve months after the surgery the actuarial survival of the patients was 73% and the actuarial patency of the homografts was 56%. In our preliminary experience, we have not observed any significant difference in terms of clinical outcome by using fresh rather than cryopreserved homografts. In the near future it will be our policy to employ only cryopreserved homografts. Moreover, we will extend vessel harvesting to nonheart-beating donors, thus maximizing retrieval. The aforementioned solutions will supply the best graft availability to obtain dimensional and ABO compatibility between donors and recipients.


Assuntos
Artérias/transplante , Prótese Vascular/efeitos adversos , Criopreservação , Infecções Relacionadas à Prótese/cirurgia , Adulto , Idoso , Feminino , Humanos , Itália , Masculino , Pessoa de Meia-Idade , Transplante Homólogo , Resultado do Tratamento , Grau de Desobstrução Vascular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA